- Home
- ONCY vs OTLK Comparison
ONCY vs OTLK Comparison
Compare ONCY & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- OTLK
- Stock Information
- Founded
- ONCY 1998
- OTLK 2010
- Country
- ONCY Canada
- OTLK United States
- Employees
- ONCY N/A
- OTLK N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ONCY Health Care
- OTLK Health Care
- Exchange
- ONCY Nasdaq
- OTLK Nasdaq
- Market Cap
- ONCY 49.1M
- OTLK 48.3M
- IPO Year
- ONCY 1999
- OTLK 2016
- Fundamental
- Price
- ONCY $0.92
- OTLK $1.77
- Analyst Decision
- ONCY Strong Buy
- OTLK Strong Buy
- Analyst Count
- ONCY 4
- OTLK 5
- Target Price
- ONCY $4.33
- OTLK $9.60
- AVG Volume (30 Days)
- ONCY 1.4M
- OTLK 793.2K
- Earning Date
- ONCY 07-31-2025
- OTLK 08-13-2025
- Dividend Yield
- ONCY N/A
- OTLK N/A
- EPS Growth
- ONCY N/A
- OTLK N/A
- EPS
- ONCY N/A
- OTLK 0.83
- Revenue
- ONCY N/A
- OTLK N/A
- Revenue This Year
- ONCY N/A
- OTLK N/A
- Revenue Next Year
- ONCY N/A
- OTLK $379.84
- P/E Ratio
- ONCY N/A
- OTLK $2.15
- Revenue Growth
- ONCY N/A
- OTLK N/A
- 52 Week Low
- ONCY $0.33
- OTLK $0.87
- 52 Week High
- ONCY $1.53
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- ONCY 78.48
- OTLK 52.03
- Support Level
- ONCY $0.71
- OTLK $1.56
- Resistance Level
- ONCY $0.81
- OTLK $1.75
- Average True Range (ATR)
- ONCY 0.09
- OTLK 0.12
- MACD
- ONCY 0.02
- OTLK -0.01
- Stochastic Oscillator
- ONCY 89.43
- OTLK 38.14
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.